Previous Close | 2.1700 |
Open | 2.3299 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 2.1700 - 2.1700 |
52 Week Range | 0.8000 - 3.9700 |
Volume | |
Avg. Volume | 725 |
Market Cap | 3.537M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 70.00 |
EPS (TTM) | 0.0310 |
Earnings Date | Aug 30, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.33 |
Expanding Reach in Rapidly Growing Ketamine Therapy MarketLOS ANGELES, March 22, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) is thrilled to announce the successful acquisition of Keta Media, LLC, dba Ketamine Media (“Ketamine Media”) as of March 17, 2023. Ketamine Media is the nation's foremost advertising company dedicated to raising awareness about the clinical use of ketamine. The agreement with Ketamine Media was initially annou
Expanding Reach in Rapidly Growing Ketamine Therapy MarketLOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) is thrilled to announce the successful acquisition of Keta Media, LLC, dba Ketamine Media (“Ketamine Media”) as of March 17, 2023. Ketamine Media is the nation's foremost advertising company dedicated to raising awareness about the clinical use of ketamine. The agreement with Ketamine Media was initially annou
LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), announced today that it has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination with Braxia Scientific Corp. ("Braxia"), (the "Proposed Transaction"). The Company's news release dated January 27, 2023, contained full details of the Proposed Transaction. CEO of Irwin Naturals, Klee Irwin, expressed disappointment on the